Confluence Investment Management LLC raised its position in Becton Dickinson and Co. (NYSE:BDX) by 3.7% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 70,337 shares of the company’s stock after buying an additional 2,518 shares during the period. Confluence Investment Management LLC’s holdings in Becton Dickinson and were worth $12,642,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of BDX. Iowa State Bank acquired a new position in Becton Dickinson and during the second quarter worth approximately $137,000. Fulton Bank N.A. raised its stake in shares of Becton Dickinson and by 12.7% in the second quarter. Fulton Bank N.A. now owns 2,943 shares of the company’s stock worth $499,000 after buying an additional 332 shares in the last quarter. Leith Wheeler Investment Counsel Ltd. purchased a new stake in shares of Becton Dickinson and during the second quarter worth $401,000. Integrated Investment Consultants LLC raised its stake in shares of Becton Dickinson and by 1.0% in the second quarter. Integrated Investment Consultants LLC now owns 1,627 shares of the company’s stock worth $276,000 after buying an additional 16 shares in the last quarter. Finally, Toth Financial Advisory Corp raised its stake in shares of Becton Dickinson and by 2.0% in the second quarter. Toth Financial Advisory Corp now owns 23,681 shares of the company’s stock worth $4,016,000 after buying an additional 460 shares in the last quarter. 81.35% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Shares of Becton Dickinson and Co. (NYSE:BDX) traded up 1.67% during mid-day trading on Tuesday, hitting $173.16. The stock had a trading volume of 595,327 shares. The stock’s 50-day moving average price is $171.40 and its 200-day moving average price is $172.45. The firm has a market cap of $36.77 billion, a PE ratio of 38.57 and a beta of 1.04. Becton Dickinson and Co. has a 52-week low of $129.50 and a 52-week high of $181.76.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, November 3rd. The company reported $2.12 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.09 by $0.03. The firm had revenue of $3.23 billion for the quarter, compared to the consensus estimate of $3.22 billion. Becton Dickinson and had a return on equity of 24.45% and a net margin of 7.82%. The company’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.94 earnings per share. On average, analysts anticipate that Becton Dickinson and Co. will post $9.52 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 30th. Stockholders of record on Friday, December 9th will be issued a $0.73 dividend. The ex-dividend date of this dividend is Wednesday, December 7th. This represents a $2.92 annualized dividend and a dividend yield of 1.71%. This is an increase from Becton Dickinson and’s previous quarterly dividend of $0.66. Becton Dickinson and’s payout ratio is currently 58.54%.

WARNING: “Confluence Investment Management LLC Purchases 2,518 Shares of Becton Dickinson and Co. (BDX)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was stolen and reposted in violation of US and international copyright & trademark law. The original version of this article can be viewed at http://www.dailypolitical.com/2016/11/29/confluence-investment-management-llc-purchases-2518-shares-of-becton-dickinson-and-co-bdx.html.

A number of equities research analysts recently weighed in on the company. Leerink Swann restated a “hold” rating on shares of Becton Dickinson and in a research report on Tuesday, August 9th. Cowen and Company restated an “outperform” rating and set a $185.00 price objective on shares of Becton Dickinson and in a research report on Tuesday, August 16th. Jefferies Group restated a “buy” rating on shares of Becton Dickinson and in a research report on Friday, August 5th. Deutsche Bank AG restated a “buy” rating and set a $189.00 price objective (down previously from $197.00) on shares of Becton Dickinson and in a research report on Friday, November 4th. Finally, Zacks Investment Research upgraded Becton Dickinson and from a “hold” rating to a “buy” rating and set a $200.00 price objective on the stock in a research report on Wednesday, November 9th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. Becton Dickinson and presently has an average rating of “Buy” and a consensus target price of $175.65.

In other news, insider Linda M. Tharby sold 11,704 shares of Becton Dickinson and stock in a transaction dated Tuesday, September 6th. The stock was sold at an average price of $177.27, for a total value of $2,074,768.08. Following the transaction, the insider now owns 22,146 shares in the company, valued at $3,925,821.42. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Stephen Sichak sold 10,352 shares of Becton Dickinson and stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $176.10, for a total value of $1,822,987.20. Following the completion of the transaction, the insider now owns 26,892 shares in the company, valued at approximately $4,735,681.20. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

5 Day Chart for NYSE:BDX

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co. (NYSE:BDX).

Receive News & Ratings for Becton Dickinson and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Co. and related companies with MarketBeat.com's FREE daily email newsletter.